GWOXI Stem Cell Secures Taiwan Invention Patent for Stem Cell-Derived Composition in Wound Healing
Gwo Xi Stem Cell (TPEx: 6704) today announced the grant of a Taiwan invention patent (Patent No. I897580) titled “Pharmaceutical Composition for Wound Repair and Its Preparation Method.” This patented technology leverages Conditioned Medium of Specific Stem Cell-Derived Factors (SpSF-CM), which have demonstrated significant therapeutic effects in promoting wound healing.
Chronic wounds, such as pressure ulcers and foot ulcers, are frequently observed in patients with chronic illnesses or prolonged immobility. Without adequate care, these conditions considerably increase the risk of infection. According to the Taiwan Ministry of Health and Welfare (MOHW), the prevalence of pressure ulcers among bedridden or mobility-impaired patients reaches 33%. These ulcers are often complicated by life-threatening conditions such as sepsis and osteomyelitis, resulting in a mortality rate more than four times higher than that of the general hospitalized patients.
Preclinical data indicate that SpSF-CM demonstrates up to two-fold enhancement in wound repair capacity compared to conventional stem cell-derived conditioned medium (CnSF-CM). In wound healing assay, wounds treated with SpSF-CM achieved a closure rate of 90.73% within 48 hours, compared to only 54.09% with CnSF-CM, highlighting the strong regenerative potential of SpSF-CM in wound repair.
Moreover, further analysis showed that SpSF-CM contains over ten cytokines and growth factors, with concentrations up to 20,000 times higher than those in CnSF-CM. These preliminary findings not only highlight the therapeutic potential of SpSF-CM in wound management but also indicate its broader applicability across multiple indications, including metabolic disorders, neurodegenerative diseases, osteoarthritis, and cardiovascular diseases, offering new avenues in regenerative medicine.
This specialized culture medium technology has already been awarded funding under the 2022 Hsinchu County Small Business Innovation Research (SBIR) program and received the Innovation R&D Star Award, underscoring both the innovation, market potential, and further enhancing the industrial and clinical value of the newly granted patent.
Gwo Xi Stem Cell remains dedicated to developing novel stem cell medicines, with strong manufacturing capabilities spanning upstream, midstream, and downstream segments of the cell therapy industry chain. By maintaining strong investment in innovation, research, and professional talent development, the company has achieved multiple forward-looking translational research milestones, with several products already advancing into late-stage clinical trials. Looking ahead, Gwo Xi Stem Cell will continue to position Taiwan as its R&D and manufacturing hub, expand into high-value niche markets, strengthen its intellectual property portfolio, and collaborate with strategic partners to enhance its presence in the global regenerative medicine arena.